Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions

Oncogene

Volumn 29, Issue 6, 2010, Pages 811-821

  Akech, J ^a   Wixted, J J ^a   Bedard, K ^a   Van Der Deen, M ^a   Hussain, S ^a   Guise, T A ^b   Van Wijnen, A J ^a   Stein, J L ^a   Languino, L R ^a   Altieri, D C ^a   Pratap, J ^a   Keller, E ^c   Stein, G S ^a   Lian, J B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Bone metastasis; Prostate cancer tissue arrays; Runx2

Indexed keywords

COLLAGENASE 3; GELATINASE B; INTERLEUKIN 8; MATRIGEL; OSTEOPONTIN; PARATHYROID HORMONE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TISSUE MICROARRAY;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, SCID; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; PROSTATIC NEOPLASMS; TIBIA; TISSUE ARRAY ANALYSIS; TRANSCRIPTIONAL ACTIVATION;

EID: 76849112495     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.389     Document Type: Article

References (44)

1. Altieri DC. (2008). New wirings in the survivin networks. Oncogene 27: 6276-6284.
2. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y et al. (2007). Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67: 6854-6862.
3. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. (2008). RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104.
4. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB et al. (2004). Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated osteolytic disease. Cancer Res 64: 4506-4513.
5. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ et al. (2003). Osteoblast-related transcription factors Runx2 (Cbfa1/ AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63: 2631-2637.
6. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA et al. (2005). Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65: 11001-11009.
7. Blyth K, Cameron ER, Neil JC. (2005). The runx genes: gain or loss of function in cancer. Nat Rev Cancer 5: 376-387.
8. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M et al. (2001). Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57: 611-616.
9. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy Jr JD et al. (2007). Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21: 486-498.
10. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S et al. (2004). Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64: 994-999.
11. Deryugina EI, Quigley JP. (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34.
12. Edwards CM, Zhuang J, Mundy GR. (2008). The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
13. Egeblad M, Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
14. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M et al. (2003). Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278: 50402-50411.
15. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D et al. (2006). Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66: 248-256.
16. Glinsky GV, Glinskii AB, Berezovskaya O, Smith BA, Jiang P, Li XM et al. (2006). Dual-color-coded imaging of viable circulating prostate carcinoma cells reveals genetic exchange between tumor cells in vivo, contributing to highly metastatic phenotypes. Cell Cycle 5: 191-197.
17. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS et al. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12: 6213s-6216s.
18. Hall CL, Kang S, MacDougald OA, Keller ET. (2006). Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97: 661-672.
19. Hassan MQ, Javed A, Morasso MI, Karlin J, Montecino M, van Wijnen AJ et al. (2004). Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3, and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol Cell Biol 24: 9248-9261.
20. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, Chung LW. (2005). Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65: 2303-2313.
21. Inman CK, Shore P. (2003). The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278: 48684-48689.
22. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ et al. (2005). Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102: 1454-1459.
23. Keller ET, Brown J. (2004). Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91: 718-729.
24. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. (2007). Molecular biology of bone metastasis. Mol Cancer Ther 6: 2609-2617.
25. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J et al. (2008a). Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118: 2697-2710.
26. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P et al. (2008b). Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27: 596-603.
27. Liao J, McCauley LK. (2006). Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25: 559-571.
28. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S et al. (2005). Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33: 44-50.
29. Mundy GR. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
30. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA et al. (2003). Cell growth regulatory role of Runx2 during proliferative expansion of pre-osteoblasts. Cancer Res 63: 5357-5362.
31. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS et al. (2005). The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25: 8581-8591.
32. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL et al. (2006). Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25: 589-600.
33. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD et al. (2008). Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68: 7795-7802.
34. Roca H, Varsos Z, Pienta KJ. (2008). CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/ AKT-dependent survivin up-regulation. J Biol Chem 283: 25057-25073.
35. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. (2008). Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180: 1154-1160.
36. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S et al. (2000). Rapid ('warm') autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6: 1038-1045.
37. Selvamurugan N, Jefcoat SC, Kwok S, Kowalewski R, Tamasi JA, Partridge NC. (2006). Overexpression of Runx2 directed by the matrix metalloproteinase-13 promoter containing the AP-1 and Runx/RD/Cbfa sites alters bone remodeling in vivo. J Cell Biochem 99: 545-557.
38. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. (2005). Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 115: 1210-1220.
39. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al. (1994). Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581.
40. Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L, Hauschka PV. (2008). VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta(3)-integrin. Matrix Biol 27: 589-599.
41. Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK, Lee SH et al. (2007). Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 445: 442-446.
42. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA et al. (2007a). Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 104: 19861-19866.
43. Zaidi SK, Young DW, Javed A, Pratap J, Montecino M, van WA et al. (2007b). Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 7: 454-463.
44. Zayzafoon M, Abdulkadir SA, McDonald JM. (2004). Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279: 3662-3670.